drugset
drugset / Trial / NCT04648865

A Study of LY3537031 in Healthy Participants

NCT04648865 ↗

Phase 1 Completed 40 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3537031 in healthy participants. The blood tests will be performed to check how much LY3537031 gets into the bloodstream, how long the body takes to eliminate it and how body handles LY3537031. Each participant will receive a single dose of LY3537031 or placebo. The study will last up to approximately 71 days for each participant, including screening.

Timeline

Start
2020-12-09
Primary completion
2021-06-04
Completion
2021-06-04

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3537031 Unknown — Subcutaneous

Indications

No indication recorded.